Making Better Influenza Virus Vaccines? by Palese, Peter
Killed and live influenza virus vaccines are effective in
preventing and curbing the spread of disease, but new
technologies such as reverse genetics could be used to
improve them and to shorten the lengthy process of prepar-
ing vaccine seed viruses. By taking advantage of these
new technologies, we could develop live vaccines that
would be safe, cross-protective against variant strains, and
require less virus per dose than conventional vaccines.
Furthermore, pandemic vaccines against highly virulent
strains such as the H5N1 virus can only be generated by
reverse genetics techniques. Other technologic break-
throughs should result in effective adjuvants for use with
killed and live vaccines, increasing the number of available
doses. Finally, universal influenza virus vaccines seem to
be within reach. These new strategies will be successful if
they are supported by regulatory agencies and if a robust
market for influenza virus vaccines against interpandemic
and pandemic threats is made and sustained. 
I
nfluenza virus vaccines were first developed in the
1940s and consisted of partially purified preparations of
influenza viruses grown in embryonated eggs. Because of
substantial contamination by egg-derived components,
these killed (formaldehyde-treated) vaccines were highly
pyrogenic and lacking in efficacy. A major breakthrough
came with the development of the zonal ultracentrifuge in
the 1960s (invented by Norman G. Anderson) (1). This
technology, which originated from uses for military pur-
poses, revolutionized the purification process and industri-
al production of many viruses for vaccines. To this day, it
remains the basis for the manufacturing process of our
influenza virus vaccines.
Current influenza virus vaccines consist of 3 compo-
nents: an H1N1 (hemagglutinin [HA] subtype 1; neu-
raminidase [NA] subtype 1), an H3N2 influenza A virus,
and an influenza B virus. Specifically, the 2005–2006 vac-
cine formulation is made up of the A/New Caledonia/20/99
(H1N1), A/California/7/2004 (H3N2), and B/Shanghai/
361/2002 viruses. Changes in the HA of circulating virus-
es (antigenic drift) require periodic replacement of the vac-
cine strains during interpandemic periods. The World
Health Organization publishes semiannual recommenda-
tions for the strains to be included for the Northern and
Southern Hemispheres (2). To allow sufficient time for
manufacture, in the United States the US Food and Drug
Administration (FDA) determines in February which vac-
cine strains should be included in the following winter’s
vaccine. Unfortunately, FDA recommendations are not
always optimal. For example, in 2003 FDA rejected the
use of the most appropriate H3N2 strain, A/Fujian/411/
2002, and instead again used the same strain as in the 2002
formulation. This decision was made primarily because the
A/Fujian/411/2002 strain had first been isolated in Madin
Darby canine kidney (MDCK) cells rather than in embry-
onated eggs. Use of MDCK cells for virus isolation is not
allowed by FDA’s rules, which do not yet encompass
advanced technologies or scientifically sound purification
procedures based on limiting dilutions or cloning with
DNA. Because of this bureaucratic roadblock, the H3N2
component of the 2003–2004 influenza virus vaccine was
antigenically “off” and showed suboptimal efficacy. One
hundred fifty-three pediatric deaths were associated with
influenza infections during the 2003–2004 season in 40
states, whereas only 9 such deaths had been reported in the
following season (3). Also, because the cumbersome clas-
sical reassortment technique used for preparing the appro-
priate seed strains makes the yearly process of
manufacturing influenza virus vaccines unnecessarily
lengthy, new variants first appearing early in the season are
rarely considered for the vaccine formulation of the fol-
lowing winter.
Currently Licensed Influenza Virus Vaccines
Most influenza virus vaccines used in the United States
and Europe consist of embryonated egg-grown and
formaldehyde-inactivated preparations, which, after purifi-
cation, are chemically disrupted with a nonionic detergent
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show lower pyrogenicity than whole virus vaccines. In
general, 1 dose for adults contains the equivalent of 45 µg
HA (15 µg HA for each of the 3 antigenic components).
This dose is approximately the amount of purified virus
obtained from the allantoic fluid of 1 infected embryonat-
ed egg. If 100 million doses of killed influenza virus vac-
cine are prepared, the manufacturer has to procure 100
million embryonated eggs. Clearly, this manufacturing
process is dependent on the timely availability of embry-
onated eggs and the vaccine seed strains to be used in a
particular season. Most of these prototype seed strains are
provided to the manufacturers by government agencies,
which create high-yielding strains through classical reas-
sortment with a high-yielding laboratory strain,
A/PR/8/34, following the procedures designed by
Kilbourne (4). Unfortunately, only (high-yielding) influen-
za A viruses can be made in this way, and even with the A
types, the 6:2 reassortants (HA and NA from recently cir-
culating strains and the remaining 6 genes from A/PR/8/34
virus) are sometimes not easily obtained. This time-con-
suming process of reassortment is then followed by repeat-
ed passaging of the strain in embryonated eggs to allow for
egg adaptation and growth enhancement. Influenza B virus
prototype strains with good growth characteristics are usu-
ally obtained by direct and repeated passaging in embry-
onated eggs without attempting to generate reassortants.
Although the manufacturing process is time-consuming,
these killed influenza Aand B virus vaccines are the work-
horses for vaccination against influenza and have been
shown time and again to be highly effective.
The second major class of viral vaccines consists of live
viruses. The only FDA-licensed product against influenza
is the cold-adapted attenuated vaccine. It is based on work
originally done by Maassab’s laboratory (5) and later by
Murphy and colleagues (6). Influenza virus was passaged
at 25°C in tissue culture (chicken kidney cells) and in
embryonated eggs. This modified Jennerian approach
resulted in a cold-adapted, temperature-sensitive, and
highly attenuated master strain. The annually updated vac-
cine strains are generated in the laboratory by reassortment
with viruses more closely related to the currently circulat-
ing ones. The resulting vaccine strains (both A and B
types) are 6:2 reassortants with the 6 nonsurface protein
genes derived from the cold-adapted master strains and the
HA and NA from circulating A and B viruses, reflecting
the changing antigenicity. These cold-adapted influenza
virus vaccines are easily administered by nasal spray. They
induce local mucosal neutralizing immunity and cell-
mediated responses that may be longer lasting and more
cross-protective than those elicited by chemically inacti-
vated (killed) vaccine preparations. Vaccine efficacy in
vaccine-naive children 6 months to 18 years of age is high
(range 73%–96%). In children revaccinated for a second
season, vaccine efficacy climbs to 82% to 100% (7).
Need for Improvement?
Despite the obvious efficacy of both killed and live
influenza virus vaccines, there is room for new develop-
ments. Among the critical issues in developing new and
better vaccines are the following: price per dose, speed of
production, ease of production, choice of substrates to
grow the virus in or to express viral antigens, cross-protec-
tion for variant strains, efficacy in general and in immuno-
logically naive populations, safety, and acceptance by the
regulatory agencies and the public.
New Adjuvants 
Most of the current inactivated influenza virus vaccines
do not contain an adjuvant. To stretch the available supply,
antigen-sparing adjuvant approaches should be considered
(8). Alum is an adjuvant that has been approved by the
FDAfor use in several vaccines. MF59, a proprietary adju-
vant from Chiron (Emeryville, CA, USA), has also been
successfully used in several countries (other than the
United States). If, under adjuvant conditions, a fifth or a
tenth of the antigenic mass currently present per vaccine
dose (45 µg of HA protein) would suffice to stimulate an
adequate protective response, a big supply problem would
be solved. 
Many adjuvants are now under investigation.
Liposome-like preparations containing cholesterol and
viral particles (immune-stimulating complexes) have been
successfully used in mice (9) by subcutaneous and
intranasal administration. Another adjuvant strategy
involves the use of heat-labile Escherichia coli toxin com-
plexed with lecithin vesicles and killed trivalent influenza
virus preparations for intranasal administration (10).
Although this specific vaccine has been withdrawn
because of Bell’s palsy cases associated with its adminis-
tration, similar approaches may become more acceptable
in the future if these safety issues can be resolved. Much
work is also currently being conducted on synthetic adju-
vants, such as synthetic lipid A, muramyl peptide deriva-
tives, and cationic molecules (11). Also, Ichinohe et al.
showed that poly (I:C) is a promising new and effective
intranasal adjuvant for influenza virus vaccines (12). 
Genetically Engineered Live and 
Killed Influenza Virus Vaccines
As indicated, current FDA-licensed influenza vaccines
are based on technologies developed in the 1960s and ear-
lier. Through the breakthrough of reverse genetics tech-
niques (13–15), infectious influenza viruses from plasmid
DNAs transfected into tissue culture cells can now be res-
cued. This technology permits the construction of high-
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a good-growing laboratory strain with the HA and NA
DNAs obtained by cloning relevant genes from currently
circulating viruses. Thus, within a 1- to 2-week period, the
appropriate seed viruses could be generated for distribution
to the manufacturers. The backbones of the 6:2 recombi-
nant viruses could be prepared, tested, and distributed in
advance. Similar approaches can be envisioned for the
manufacturing of live, cold-adapted influenza virus vac-
cines. In this case, the backbone would consist of the 6
genes of the cold-adapted master strain. Again, the HA and
NAof the currently circulating strains would be cloned and
used for rescue in the plasmid-only reverse genetics sys-
tem. Such an approach would have several advantages over
the present manufacturing process. First, it would dramati-
cally accelerate the timeframe for obtaining seed viruses for
annual production and thus allow more time to select the
appropriate antigenic seed strains. Second, it would stan-
dardize the seed viruses to be used. Regulatory agencies do
not insist on a sequenced product to be given to humans but
instead allow only partially characterized products for
annual immunization. Third, DNA cloning may eliminate
any adventitious agents present in the throat washings of
the original isolate. Finally, in the case of the current high-
ly pathogenic H5 strains, viruses with that HA (containing
a multibasic HA1/HA2 cleavage site) kill embryonated
eggs, making it difficult to use eggs as growth substrate.
Also personnel involved in manufacturing those vaccines
might be in danger of becoming infected. Thus, the HA of
these virulent strains will need to be modified. Removal of
the basic cleavage peptide by reverse genetics results in a
virus that is attenuated for embryonated eggs, thus allowing
high yields to be attained. Modification by reverse genetics
results in a product that is easier to manufacture and safer
to handle (this includes safety considerations for all persons
working with the virus).
Live Influenza Virus Vaccines with Altered
Nonstructural Protein 1 Genes
The ability to site specifically engineering changes in
the influenza virus genome also allows us to consider
novel vaccine approaches. We have demonstrated that the
nonstructural protein 1 (NS1) of influenza viruses has
interferon antagonist activity (16). Influenza viruses that
lack NS1 cannot counter the interferon response of the
host. Thus, infection of cells with a virus that lacks NS1
results in the induction of interferon and blockage of virus
replication. When truncations are made in NS1, viruses are
generated with an intermediate activity, which enables
them to replicate in the host and also to induce an interfer-
on response. By engineering a virus with intermediate vir-
ulence and ability to induce interferon, one can construct
ideal influenza virus vaccines that are both attenuated and
highly immunogenic (17–20). Interferon appears to be an
excellent adjuvant that enhances production of
immunoglobulins and contributes to the activation of den-
dritic cells required for antigen presentation (21–23). We
thus believe that, per virus particle made or antigen mole-
cule delivered, the immune response will be enhanced
compared to that of conventional live or killed virus vac-
cines. This process should translate into lower doses of live
virus vaccine required to induce a robust and protective
immune response. If a hundredfold lower dose is required,
many more people could have access to influenza virus
vaccines. This issue is clearly of paramount importance in
the event of a new pandemic virus. Moreover, a live virus
vaccine may give protective immunity in immunological-
ly naive populations after a single administration, while
killed virus vaccines may require high antigenic doses and
a prime-boost regimen to protect against a pandemic
strain. It may turn out that only live influenza virus vac-
cines can provide the necessary protection in case of a new
pandemic. Because live influenza virus vaccines appear to
be more effective in immunologically naive populations
and they can be intranasally administered, they would rep-
resent a more economical way of vaccinating large num-
bers of people.
Replication-defective Vaccines
Other promising approaches concern the use of replica-
tion-deficient preparations. For example, virus particles
that lack the gene for the nuclear export protein (NEP; for-
merly NS2) will go through a single cycle of replication
(without forming infectious particles) (24). Virus particles
without the M2 gene may also fit this formula (25). Mass
production of defective viruses can be achieved by using
complementing cell lines. The administration of virosomes
(consisting of reconstituted viral envelopes that lack
RNA), and the use of viruslike particles made by expres-
sion of viral proteins have also been shown to be effective
immunization strategies against influenza (26,27). Yet
another approach concerns DNAvaccination in humans by
using plasmids that express >1 foreign gene.
Unfortunately, this approach has been less than convincing
since it appears to work best in mice and other small mam-
mals (28). Thus, the jury is still out as to whether this
approach is reasonable for improving influenza virus vac-
cines in humans.
Universal Vaccines?
Influenza viruses continue to undergo antigenic drift,
which is mostly reflected in accumulating changes in the
HA. This fact requires us to change the vaccine formula-
tion or at least to reexamine the seed strains on an annual
basis. Unfortunately, predicting the evolutionary change of
the viral HA has not been reliable (29). Thus, short of
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the emergence of a particular pandemic strain (avian or oth-
erwise) is unlikely (30). A more realistic approach is the
design of more cross-protective vaccines for use in inter-
pandemic years and during pandemics. Neirynck et al. have
designed vaccines based on the conserved extracellular por-
tion of the M2 protein fused to the hepatitis B core protein
(31). Such an immunogen may induce a cross-reactive
response in the vaccinated host. Similarly, immunization
with the NA antigen is likely to induce responses that are
more cross-reactive than those by the more variable HA
(32). In both cases, however, protection will require
immune responses that are more vigorous than what is seen
after natural infection. Antibodies against NA and M2 pro-
teins in infected humans are generally not protective. Thus
vaccines consisting of NA or M antigens would need to be
adjuvanted or otherwise made to induce a dramatically
enhanced immune response. Alternatively, genetically
engineered viruses could be generated, which would
express several variant antigens or epitopes, thereby
achieving a more cross-protective immunization. Chimeric
HA recombinant viruses that express an additional 140
amino acids have recently been described (33). Such genet-
ically engineered viruses may present several conserved
immunogenic epitopes on the viral surface, which would be
a first step toward a more universal influenza vaccine.
Conclusions
Technologies are now in place to design and construct
new influenza virus vaccines that have the potential to be
cheaper and more cross-protective than current vaccine
preparations, while at the same time being equally safe.
The greatest problems for new and better vaccines appear
to be associated with regulatory hurdles and the lack of an
adequate market. Regarding the bureaucratic restrictions
levied on vaccines by licensing agencies, the message has
to come through “that small risks have to be tolerated for
larger ones to be avoided” (34). Also, the message needs to
be disseminated to the general public that vaccines have
the best cost-benefit ratio of any medical treatment and
that limitations of the tort law should be considered where
vaccines are concerned. The public often views vaccines
and prophylactic treatments in general as being of low pri-
ority. Many people also believe they should be free. Thus,
the absence of a robust commercial market is a major dif-
ficulty, resulting in slow progress for research and devel-
opment of new influenza vaccines and in dangerously thin
supply lines. In fact, we are far from being prepared to deal
with regular influenza outbreaks, and adequate measures
to cope with a pandemic outbreak are only now being con-
sidered, but are not yet in place (35,36; and http://www.
washingtonpost.com/wp-dyn/content/article/2005/11/01/
AR2005110101100.html).
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